Infusion of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) into the right common carotid artery produced hemiparkinsonian syndrome on contralateral limbs in 5 rhesus monkeys. The hemiparkinsonian syndrome produce...Infusion of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) into the right common carotid artery produced hemiparkinsonian syndrome on contralateral limbs in 5 rhesus monkeys. The hemiparkinsonian syndrome produced responded to madopar medication and the circling motion changed from toward the MPTP-treated side to away from the MPTP-treated side. Long term use of madopar developed a peak-dose dyskinesia of the face and limbs at the contralateral side. The toxic effect of MPTP was confirmed biochemically by reduction of nigrostriatal DA and histologically by degeneration of nigral neurons on the MPTP-treated side. It is concluded that this hemiparkinsonian monkey model will be of value in the elucidation of the neural mechanism underlying L-DOPA or DA agonists induced dyskinesia in Parkinson’s disease and in the search for newer methods of treatment which would produce less dyskinesia.展开更多
Mice treated with large dose of MPTP showed a reduction in the levels of DA, 5-HT and their metabolites in the striatum. The average levels as compared with the control were reduced by 94% for DA (P【0.001), 61% for D...Mice treated with large dose of MPTP showed a reduction in the levels of DA, 5-HT and their metabolites in the striatum. The average levels as compared with the control were reduced by 94% for DA (P【0.001), 61% for DOPAC (P【0.05), 65% for HVA (P【0.01). 5-HT and 5-HIAA were lower than detection limits. In mice pretreated with budipine, although the striatal dopamine level was also reduced, mean DA and 5-HT levels were significantly higher than those in mice given MPTP alone. This result suggested that budipine can partially prevent the MPTP neurotoxicity.展开更多
文摘Infusion of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) into the right common carotid artery produced hemiparkinsonian syndrome on contralateral limbs in 5 rhesus monkeys. The hemiparkinsonian syndrome produced responded to madopar medication and the circling motion changed from toward the MPTP-treated side to away from the MPTP-treated side. Long term use of madopar developed a peak-dose dyskinesia of the face and limbs at the contralateral side. The toxic effect of MPTP was confirmed biochemically by reduction of nigrostriatal DA and histologically by degeneration of nigral neurons on the MPTP-treated side. It is concluded that this hemiparkinsonian monkey model will be of value in the elucidation of the neural mechanism underlying L-DOPA or DA agonists induced dyskinesia in Parkinson’s disease and in the search for newer methods of treatment which would produce less dyskinesia.
文摘Mice treated with large dose of MPTP showed a reduction in the levels of DA, 5-HT and their metabolites in the striatum. The average levels as compared with the control were reduced by 94% for DA (P【0.001), 61% for DOPAC (P【0.05), 65% for HVA (P【0.01). 5-HT and 5-HIAA were lower than detection limits. In mice pretreated with budipine, although the striatal dopamine level was also reduced, mean DA and 5-HT levels were significantly higher than those in mice given MPTP alone. This result suggested that budipine can partially prevent the MPTP neurotoxicity.
